SCHEMBL4062585

SCHEMBL4062585

Fc1cc(F)cc(-c2nc3ccc(-c4ccco4)cc3o2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 6/20 0.52
ALOX5 P09917 1/20 0.49
ADORA2A P29274 2/20 0.47
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
RAB9A P51151 2/20 0.44
CASP3 P42574 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
VSIR Q9H7M9 1/20 0.42
PIK3R1 P27986 1/20 0.42
PIK3CA P42336 1/20 0.42
ESR1 P03372 4/20 0.42
ESR2 Q92731 4/20 0.42
MEN1 O00255 1/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059581 0.90 VSIR (0.54) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4059341 0.89 GPR119 (0.43) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4061714 0.85 ALOX5 (0.56) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4054203 0.83 GPR119 (0.49) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4053161 0.81 ALOX5 (0.52) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4051830 0.79 RAB9A (0.55) GPR119ALOX5KDM4ENPC1ALDH1A1
SCHEMBL4058272 0.79 RAB9A (0.56) GPR119ALOX5KDM4ENPC1ALDH1A1
SCHEMBL4051901 0.79 NPC1 (0.62) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4063034 0.79 PDE4C (0.57) GPR119ALOX5ADORA2AKDM4ENPC1
SCHEMBL4055539 0.79 GPR119 (0.45) GPR119ALOX5KDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B GPR119 1677/4885ALOX5 1869/4885ADORA2A 3069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.